Soligenix (SNGX) Other Accumulated Expenses (2017 - 2026)
Soligenix's (SNGX) quarterly Other Accumulated Expenses came in at $390894.0 in Q1 2026, down 80.61% YoY from $2.0 million in Q1 2025, and up 43.66% on a QoQ basis from $272088.0 in Q4 2025.
Soligenix (SNGX) Other Accumulated Expenses (2017 - 2026) Analysis & Trends
Soligenix (SNGX) has 10 years of Other Accumulated Expenses data on file, last reported at $390894.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 80.61% year-over-year to $390894.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $390894.0 (down 80.61% YoY) and the FY2025 annual result came in at $272088.0, down 77.77% from the prior year.
- Other Accumulated Expenses improved to $390894.0 in Q1 2026, from $272088.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $2.0 million in Q1 2025 to a low of $272088.0 in Q4 2025.
- A 5-year average of $588208.9 and a median of $423629.0 in 2022 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 2040.25% — and 2026, when it slumped 80.61%.
- Tracing SNGX's Other Accumulated Expenses over 5 years: stood at $423629.0 in 2022, then grew by 0.14% to $424218.0 in 2023, then soared by 188.48% to $1.2 million in 2024, then sank by 77.77% to $272088.0 in 2025, then jumped by 43.66% to $390894.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $390894.0 (Q1 2026), $272088.0 (Q4 2025), and $454295.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 574,428.00 |
| Mar 31, 2026 | 390,894.00 |
| Dec 31, 2025 | 272,088.00 |
| Sep 30, 2025 | 454,295.00 |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 412,206.00 |
| Jun 30, 2024 | 345,198.00 |
| Mar 31, 2024 | 531,710.00 |
| Dec 31, 2023 | 424,218.00 |
| Sep 30, 2023 | 304,636.00 |
| Jun 30, 2023 | 376,962.00 |
| Mar 31, 2023 | 437,113.00 |
| Dec 31, 2022 | 423,629.00 |
| Sep 30, 2022 | 322,230.00 |
| Jun 30, 2022 | 417,884.00 |
| Mar 31, 2022 | 594,575.00 |
| Dec 31, 2021 | 330,766.00 |
| Sep 30, 2021 | 16,952.00 |